Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d)Exhibits
|
Exhibit No. |
Document |
| 99.1 | Press release of Recro Pharma, Inc., dated July 31, 2017. |
Recro Pharma, Inc. ExhibitEX-99.1 2 d319995dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Recro Pharma Submits New Drug Application for IV Meloxicam 30mg MALVERN,…To view the full exhibit click here
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.